Plain-English translation of NCT06762717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following 500 people in China who are receiving the FARAPULSE™ Pulsed Field Ablation System, a newer technology designed to treat paroxysmal atrial fibrillation (a type of irregular heartbeat that comes and goes). Researchers want to understand how well this treatment works and how safe it is in real-world medical practice over three years of follow-up.
Paroxysmal atrial fibrillation can cause serious health problems if left untreated, and doctors need real-world data to understand how new treatment technologies perform in everyday clinical care, especially in Chinese populations.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the FARAPULSE™ procedure as planned by your doctor. After the procedure, you'll have follow-up visits and phone calls at specific time points: before you leave the hospital, at 3 months, 6 months (phone call only), 12 months, 2 years, and 3 years. The main focus is monitoring how well the treatment works and whether you experience any side effects over the three-year period.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China
Enrollment target
~500 participants
Started
October 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hui Lin
Chinese Academy of Medical Sciences, Fuwai Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.